24/7 Market News Snapshot 01 November, 2024 – Nexalin Technology, Inc. Common Stock (NASDAQ:NXL)

November 1, 2024

DENVER, Colo., 01 November, 2024 (247marketnews.com) – (NASDAQ:NXL) are discussed in this article.
Nexalin Technology, Inc. has recently witnessed a significant surge in its stock performance, with shares rising from a closing price of $2.49 to an impressive $3.03, representing a remarkable gain of 21.73%. This uptick, supported by a robust trading volume of 3.64 million shares, reflects a strong market response and heightened investor interest. The stock’s breakthrough through critical resistance levels indicates positive momentum, attracting attention in a competitive financial landscape.

In a related milestone, Nexalin proudly announced that it has regained compliance with The Nasdaq Stock Market’s minimum bid price requirement, as confirmed by a notice received on October 31, 2024. This achievement underscores the company’s commitment to enhancing shareholder value and improving its visibility in the market. CEO Mark White emphasized the importance of this compliance milestone, stating it reflects their determination to innovate and reshape treatment options for those affected by mental health and neurological disorders.

Nexalin Technology is at the forefront of designing non-invasive neurostimulation products that utilize bioelectronic technology to provide relief for individuals suffering from mental health issues. The company’s next-generation neurostimulation devices are engineered to target deep structures in the mid-brain associated with various disorders, fostering improved patient responses while minimizing side effects. Currently, the Nexalin Gen-2 15 milliamp neurostimulation device has received approval in several international markets, including China, Brazil, and Oman, highlighting its global potential.

As Nexalin advances in clinical research and seeks additional regulatory approvals worldwide, the company expresses gratitude to its supportive shareholders. This progress reinforces Nexalin’s dedication to innovation in mental health treatment and positions it for ongoing growth within the healthcare sector.

Related news for (NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.